ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)

ChengDa Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	306.27	330.85	413.28	411.34	415.59	372.96
Other Revenue	2.28	2.28	1.03	0.12	0.14	0.07
Revenue	308.55	333.13	414.3	411.46	415.73	373.04
Revenue Growth (YoY)	-25.29%	-19.59%	0.69%	-1.03%	11.44%	26.90%
Cost of Revenue	187.23	207.33	238.93	228.55	215.7	193.47
Gross Profit	121.32	125.8	175.37	182.92	200.02	179.57
Selling, General & Admin	111.33	99.58	85.59	88.01	66.83	56.31
Research & Development	92.95	93.71	27.46	19.44	17.22	18.98
Other Operating Expenses	5.68	4.28	3.57	4.15	2.47	3.41
Operating Expenses	211.13	195.86	117.69	112.65	87.95	77.65
Operating Income	-89.82	-70.06	57.68	70.27	112.08	101.92
Interest Expense	-0.89	-0.3	-	-0.2	-1.4	-2.68
Interest & Investment Income	27.3	32.81	48.19	40.25	0.26	0.47
Currency Exchange Gain (Loss)	2.4	2.4	1.45	4.7	-1.51	-3.15
Other Non Operating Income (Expenses)	3.97	2.91	-5.06	-0.16	-0.1	-0.11
EBT Excluding Unusual Items	-57.04	-32.24	102.26	114.87	109.33	96.45
Gain (Loss) on Sale of Investments	2.08	1.6	-	0.39	-	-
Gain (Loss) on Sale of Assets	0.07	0.2	0	-0.53	-0.02	41.86
Asset Writedown	-2.32	-2.53	-3.51	-3.43	-2.62	-1.85
Other Unusual Items	6.46	5.78	5.5	8.81	8.6	3.06
Pretax Income	-50.76	-27.18	104.25	120.11	115.29	139.51
Income Tax Expense	-3.06	0.46	13.15	13.63	15.01	19.91
Earnings From Continuing Operations	-47.7	-27.64	91.1	106.48	100.27	119.61
Minority Interest in Earnings	-0.45	-0.46	-0.12	0.01	0.16	1.57
Net Income	-48.15	-28.1	90.98	106.48	100.44	121.17
Net Income to Common	-48.15	-28.1	90.98	106.48	100.44	121.17
Net Income Growth	-	-	-14.56%	6.02%	-17.11%	123.47%
Shares Outstanding (Basic)	152	152	155	151	116	116
Shares Outstanding (Diluted)	152	152	155	151	116	116
Shares Change (YoY)	-1.76%	-1.75%	2.12%	30.56%	-0.00%	9.67%
EPS (Basic)	-0.32	-0.18	0.59	0.70	0.87	1.04
EPS (Diluted)	-0.32	-0.18	0.59	0.70	0.87	1.04
EPS Growth	-	-	-16.33%	-18.80%	-17.11%	103.77%
Free Cash Flow	-297.62	-257.72	-32.6	-158.03	-55.56	65.16
Free Cash Flow Per Share	-1.96	-1.70	-0.21	-1.04	-0.48	0.56
Dividend Per Share	0.200	0.200	0.200	0.188	0.281	-
Dividend Growth	-	-	6.67%	-33.34%	-	-
Gross Margin	39.32%	37.76%	42.33%	44.45%	48.11%	48.14%
Operating Margin	-29.11%	-21.03%	13.92%	17.08%	26.96%	27.32%
Profit Margin	-15.60%	-8.44%	21.96%	25.88%	24.16%	32.48%
Free Cash Flow Margin	-96.46%	-77.36%	-7.87%	-38.41%	-13.36%	17.47%
EBITDA	-41.41	-23.22	98.28	105.58	142.56	128.26
EBITDA Margin	-13.42%	-6.97%	23.72%	25.66%	34.29%	34.38%
D&A For EBITDA	48.41	46.85	40.6	35.32	30.49	26.34
EBIT	-89.82	-70.06	57.68	70.27	112.08	101.92
EBIT Margin	-29.11%	-21.03%	13.92%	17.08%	26.96%	27.32%
Effective Tax Rate	-	-	12.61%	11.35%	13.02%	14.27%
Revenue as Reported	308.55	333.13	414.3	411.46	415.73	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.